News|Articles|October 3, 2024
Concurrent Chemoradiation/Atezolizumab Does Not Improve Survival in LS-SCLC
Author(s)Russ Conroy
Fact checked by: Gina Mauro
Data show that twice-daily radiotherapy may confer improved survival vs once-daily radiation in patients with limited-stage small cell lung cancer.
Advertisement
Advertisement
The addition of atezolizumab (Tecentriq) to concurrent chemoradiotherapy (CRT) did not improve survival outcomes among patients with limited-stage small cell lung cancer (LS-SCLC), according to findings from the phase 3 NRG-LU005 trial (NCT03811002) presented at the
Advertisement
Advertisement